Press Releases

Date Title and Summary View
Aug 30, 2018
MacroGenics Announces Participation in Three Upcoming Investor Conferences

Rockville, MD , Aug. 30, 2018 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will

Aug 09, 2018
MacroGenics to Present at Wedbush PacGrow Healthcare Conference

ROCKVILLE, MD , Aug. 09, 2018 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will

Aug 07, 2018
MacroGenics Provides Update on Corporate Progress and 2nd Quarter 2018 Financial Results

ROCKVILLE, Md. , Aug. 07, 2018 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today provided an update on its corporate progress and

Jul 30, 2018
MacroGenics Announces Date of Second Quarter 2018 Financial Results Conference Call

ROCKVILLE, MD , July 30, 2018 (GLOBE NEWSWIRE) -- --  MacroGenics, Inc. (Nasdaq: MGNX) today announced that on Tuesday, August 7, 2018 , the Company will release its financial results for the quarter ended June 30, 2018 . The Company's management team will host a conference call discussing the

Jun 05, 2018
MacroGenics to Present at Jefferies Global Healthcare Conference

ROCKVILLE, MD , June 05, 2018 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will

May 07, 2018
MacroGenics to Present at Deutsche Bank Health Care Conference

ROCKVILLE, MD , May 07, 2018 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will

May 07, 2018
MacroGenics Provides Update on Corporate Progress and 1st Quarter 2018 Financial Results

ROCKVILLE, Md. , May 07, 2018 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today provided a corporate progress update and reported

Apr 30, 2018
MacroGenics Announces Date of First Quarter 2018 Financial Results Conference Call

ROCKVILLE, MD , April 30, 2018 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX) today announced that on Monday, May 7, 2018 , the Company will release its financial results for the quarter ended March 31, 2018 . The Company's management team will host a conference call discussing the Company's

Apr 02, 2018
MacroGenics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares

ROCKVILLE, MD , April 02, 2018 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced the closing of its previously

Mar 28, 2018
MacroGenics Announces Pricing of Public Offering of Common Stock

ROCKVILLE, MD , March 28, 2018 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced the pricing of an underwritten public

Mar 26, 2018
MacroGenics Announces Proposed Public Offering of Common Stock

ROCKVILLE, MD , March 26, 2018 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that it has commenced an underwritten

Mar 09, 2018
MacroGenics to Present at Cowen Health Care Conference
Rockville, MD, March 09, 2018 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will
Additional Formats
Feb 27, 2018
MacroGenics Provides Update on Corporate Progress and 2017 Financial Results
ROCKVILLE, Md., Feb. 27, 2018 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today provided a corporate progress update and reported
Additional Formats
Feb 14, 2018
MacroGenics Announces Date of Fourth Quarter and Full Year 2017 Financial Results Conference Call
ROCKVILLE, MD, Feb. 14, 2018 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that on Tuesday, February 27, 2018, the
Additional Formats
Feb 06, 2018
MacroGenics to Participate in Two Upcoming Investor Conferences
ROCKVILLE, MD, Feb. 06, 2018 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will
Additional Formats
Jan 23, 2018
MacroGenics Announces Continuation of SOPHIA Study of Margetuximab Based on Completion of Interim Futility Analysis
FDA grants Fast Track designation to margetuximab for treatment of metastatic breast cancer
Additional Formats
Jan 18, 2018
Phase 1b/2 Study of Margetuximab in Combination with Pembrolizumab Presented at 2018 ASCO Gastrointestinal Cancers Symposium
Chemotherapy-free, immunotherapeutic combination evaluated 32% Overall response rate in second-line gastric cancer patients Well tolerated in dose escalation and expansion cohorts Rockville, MD, Jan. 18, 2018 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a clinical-stage biopharmaceutical
Additional Formats
Jan 04, 2018
MacroGenics to Present at the 36th Annual J.P. Morgan Healthcare Conference
ROCKVILLE, MD, Jan. 04, 2018 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious diseases,
Additional Formats
Jan 04, 2018
MacroGenics Enters Research Collaboration with Roche to Develop a Novel Bispecific Molecule
ROCKVILLE, MD, Jan. 04, 2018 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious
Additional Formats
Dec 11, 2017
Phase 1 Data for Flotetuzumab, MacroGenics' CD123 x CD3 DART® Molecule, Presented at 59th Annual ASH Meeting
Encouraging initial anti-leukemic activity with durable responses and acceptable tolerability observed in dose expansion cohort Data supports combination with MGA012 (anti-PD-1) to potentially enhance anti-leukemic effects Rockville, MD, Dec. 11, 2017 (GLOBE NEWSWIRE) -- MacroGenics, Inc.
Additional Formats
Dec 05, 2017
MacroGenics Announces Closing of MGA012 Global Collaboration and License Agreement with Incyte
ROCKVILLE, MD, Dec. 05, 2017 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious diseases,
Additional Formats
Nov 15, 2017
MacroGenics Names Dr. Jay Siegel to its Board of Directors
ROCKVILLE, MD, Nov. 15, 2017 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious diseases,
Additional Formats
Nov 13, 2017
MacroGenics to Participate in Two Upcoming Investor Conferences
ROCKVILLE, MD, Nov. 13, 2017 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious diseases,
Additional Formats
Nov 10, 2017
MacroGenics Announces Poster Presentations at 32nd Annual SITC Meeting 2017
ROCKVILLE, Maryland, Nov. 10, 2017 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious
Additional Formats
Nov 08, 2017
MacroGenics Provides Update on Corporate Progress and Third Quarter 2017 Financial Results
ROCKVILLE, Md., Nov. 08, 2017 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious diseases,
Additional Formats